Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

Allergan to pay up to $375m for SkinMedica’s skincare business

Boosts aesthetic products division, which already includes Botox

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Dr Ian Hudson elected vice chair of CHMP

Will serve a three-year term on EMA's scientific advisory committee

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

- PMLiVE

Sweden’s Tomas Salmonson to chair EMA’s CHMP

He replaces Eric Abadie who retired in April

Allergan signs $1.4bn eye drug deal with Molecular Partners

Will develop DARPin proteins to target AMD and other eye conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links